三种头孢哌酮舒巴坦治疗鲍曼不动杆菌肺病感染的临床疗效和经济学研究

发布时间：2018-04-19 14:06

本文选题：头孢哌酮钠舒巴坦 + 鲍曼不动杆菌　；参考：《中国医院药学杂志》2017年22期

【摘要】：目的:比较三种头孢哌酮钠舒巴坦治疗鲍曼不动杆菌肺部感染临床疗效和经济性,为临床合理用药提供参考。方法:将105例鲍曼不动杆菌肺部感染患者随机分为A组、B组和C组,每组各35例,所有患者均给予吸氧、祛痰、平喘和阿米卡星(0.6 g,ivgtt,qd)等常规治疗,在常规治疗基础上,A组给予头孢哌酮钠舒巴坦(舒普深,头孢哌酮钠∶舒巴坦钠=2∶1);B组给予头孢哌酮钠舒巴坦(达力哌坦,头孢哌酮钠∶舒巴坦钠=2∶1);C组给予头孢哌酮钠舒巴坦(金抗宁,头孢哌酮钠∶舒巴坦钠=1∶1),均3 g/次,每8 h静脉滴注1次。3组疗程均为14 d。分别以临床总有效率和细菌清除率为疗效指标,采用成本-效果比(C/E)进行经济学分析。结果:A组、B组和C组的临床总有效率分别为77.14%、42.86%和68.57%,A组与B组、B组与C组比较存在统计学意义(P0.05),A组与C组间比较无显统计学意义(P0.05);细菌清除率分别为82.86%、31.43%和57.14%,组间比较均有统计学意义(P0.05);治疗成本分别为9 378.04元、4 044.04元和5 174.68元;临床总有效率的C/E分别为121.57、94.35和75.47,细菌清除率的C/E分别为113.18、129.04和90.56,A组、C组相对于B组临床总有效率的ΔC/ΔE分别为155.60、43.98,细菌清除率的ΔC/ΔE分别为103.53、43.82。敏感度分析支持成本-效果比分析结果。结论:对于临床症状严重的鲍曼不动杆菌肺部感染患者,在经济状况允许的范围内,临床可首选舒普深;对于临床症状较轻,经济状况有限的患者,首选具有经济学优势的金抗宁。
[Abstract]:Objective: to compare the efficacy and economy of three kinds of cefoperazone sodium sulbactam in the treatment of Acinetobacter baumannii pulmonary infection.Methods: 105 patients with acinetobacter baumannii pulmonary infection were randomly divided into group A (n = 35) and group C (n = 35).On the basis of routine treatment, group A was given cefoperazone sodium sulbactam (sulpoperazone sodium, cefoperazone sodium: sulbactam sodium 2: 1) group B, cefoperazone sodium sulbactam, cefoperazone sodium sulbactam, and cefoperazone sodium sulbactam.Cefoperazone sodium: sulbactam sodium: sulbactam sodium sulbactam group C was given cefoperazone sodium sulbactam (Jinkanine, cefoperazone sodium: sulbactam sodium 1: 1, 3 g / time). The course of treatment in group C was 14 days after intravenous drip every 8 hours.The total clinical effective rate and bacterial clearance rate were taken as the effective indexes, and the cost-effectiveness ratio (C / E) was used to carry out economic analysis.Results the total clinical effective rates of group B and C were 77.142.86% and 68.57%, respectively. There was no significant difference between group A and group B and group C (P 0.05), and the clearance rates of bacteria were 82.8631.43% and 57.14%, respectively.The cost of treatment was 9 378.04 yuan, 4 044.04 yuan and 5 174.68 yuan, respectively.The total clinical effective rates of C / E were 121.57% and 75.47, respectively. The C / E of bacterial clearance rate were 113.18129.04 and 90.56% respectively. The 螖 C / 螖 E of group C and B were 155.60 ~ 43.98, and the 螖 C / 螖 E of bacteria clearance were 103.53n 43.82, respectively.Sensitivity analysis supports cost-effectiveness ratio analysis results.Conclusion: for patients with severe clinical symptoms of Acinetobacter baumannii pulmonary infection, the first choice for patients with severe clinical symptoms and limited economic status is Schupin.The first choice has the economic advantage of Jin Kangning.
【作者单位】：哈励逊国际和平医院;
【分类号】：R563.1

【相似文献】